ADTX - AditxtScore shares rise 16% on launch of immune monitoring service in COVID-19

Aditx Therapeutics (ADTX) soars 14% premarket after announcing the operational launch of the AditxtScore Immune Monitoring Platform as of February 1st, 2021. The initial application of the platform will be AditxtScore for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus.The company will soon be expanding the panel to measure other components of the immune response such as cellular immunity. AditxtScore for COVID-19 will be available as a Lab Developed Test and processed at the AditxtScore Immune Monitoring Center, which will operate as a CLIA-certified reference lab.

For further details see:

AditxtScore shares rise 16% on launch of immune monitoring service in COVID-19